Oppenheimer Holdings, Inc. began coverage on shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) in a research note released on Thursday. The firm issued an outperform rating and a $12.00 price objective on the biotechnology company’s stock.
Several other analysts have also recently commented on the company. Zacks Investment Research cut Strongbridge Biopharma PLC from a buy rating to a hold rating in a research report on Thursday. ValuEngine upgraded Strongbridge Biopharma PLC from a sell rating to a hold rating in a research report on Tuesday, June 27th. Finally, HC Wainwright reiterated a buy rating on shares of Strongbridge Biopharma PLC in a research report on Wednesday, May 17th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $11.94.
Strongbridge Biopharma PLC (NASDAQ SBBP) traded up 6.38% on Thursday, reaching $7.50. The company’s stock had a trading volume of 47,576 shares. The firm has a 50-day moving average of $6.86 and a 200 day moving average of $4.63. The company’s market capitalization is $265.01 million. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $8.85.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $0.84 million. On average, equities research analysts anticipate that Strongbridge Biopharma PLC will post ($2.20) EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at approximately $474,000. Northern Trust Corp purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at approximately $1,462,000. Citigroup Inc. purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at approximately $338,000. TIAA CREF Investment Management LLC purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at approximately $449,000. Finally, Teachers Advisors LLC purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at approximately $297,000.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.
